$29.80−1.07 (−3.47%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD
Viridian Therapeutics (VRDN) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
25 figures withheld by our checks. Each blank figure names its reason.
Business engineGrowing fast: revenue compounds ~121.1%/yr (FY21→FY25), net margin −483.6%. Worth your attention in FY25: Share count (+163.2%). Visible in the receipts below.
The lines that matter · FY21–FY25
Revenue ($M)▲23359.9%
70.8
FY21→FY25CAGR +121.1%/yr
Net income ($M)▼26.9%
−342.6
FY21→FY25CAGR —
Free cash flow ($M)▼18.9%
−276.9
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+163.2%
32.3mn → 85.1mn diluted shares since FY22. Rising share count dilutes EPS. Growth must outrun it.
Capex
$495.0K
steady at 0.7% of revenue (−3.1% YoY).
What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)
-484¢ of every revenue dollar becomes profit.
Margin trend · direction beats level Operating Net
Net margin -483.6% is below the sector median. This filer reports no gross profit line, so that margin is not drawn.
The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
The annual and quarterly statements are struck on share counts that differ by a factor of 0.749, so per-share figures cannot be compared across the two tables. Each table's per-share figures are on its own share basis.
USD thousands except per-share & ratios
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | 26,309.0 | 70,849.0 | 302.0 | 314.0 | 1,772.0 | 2,963.0 | ▲23359.9% | +121.1% |
Cost of revenue | 1,527.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | — |
Gross profit | 24,782.0 | —A | —A | —A | —A | —A | — | — |
Research & development | 308,508.0 | 338,929.0 | 238,254.0 | 159,765.0 | 100,894.0 | 56,886.0 | ▲42.3% | +56.2% |
Selling, general & admin | 184,937.0 | 95,315.0 | 61,083.0 | 94,999.0 | 35,182.0 | 25,805.0 | ▲56.0% | +38.6% |
Total operating expenses | 493,445.0 | 434,244.0 | 299,337.0 | 254,764.0 | 136,076.0 | 82,691.0 | ▲45.1% | +51.4% |
Operating incomefeeds ROC rank | −468,663.0 | −363,395.0 | −299,035.0 | −254,450.0 | −134,304.0 | −79,728.0 | ▼21.5% | — |
Other income, net | 14,199.0 | 20,794.0 | 29,086.0 | 16,716.0 | 4,430.0 | 315.0 | — | — |
Pretax income | −454,464.0 | −342,601.0 | −269,949.0 | −237,734.0 | −129,874.0 | −79,413.0 | ▼26.9% | — |
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings | −453,584.0 | −342,601.0 | −269,949.0 | −237,734.0 | −129,874.0 | −79,413.0 | ▼26.9% | — |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | —B | —B | —B | —B | —B | —B | — | — |
Diluted shares (mn) | 113.59 | 85.08 | 68.19 | 45.00 | 32.32 | 11.92 | ▲24.8% | +63.5% |
| Margins | ||||||||
Gross margin91st pct in Healthcare | 94.2% | —A | —A | —A | —A | —A | — | — |
Operating margin | −1781.4% | −512.9% | −99018.2% | −81035.0% | −7579.2% | −2690.8% | ▲98505.3pp | +2177.9pp |
Net margin0th pct in Healthcare | −1724.1% | −483.6% | −89387.1% | −75711.5% | −7329.2% | −2680.2% | ▲88903.5pp | +2196.6pp |
† TTM = trailing four quarters through 2026-09-30.A Withheld: cost of revenue is not on file, so the gross margin is not measured.B Withheld by our checks.
5 more years of statements and CSV export are on Premium, and 8 more on Ultimate.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-02-26 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was Viridian Therapeutics' revenue last fiscal year?
Viridian Therapeutics reported revenue of $70.8M in fiscal 2025, up 23359.9% from fiscal 2024.
What was Viridian Therapeutics' net income?
Viridian Therapeutics reported net income of −$342.6M in fiscal 2025, a net margin of −483.6%.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

